Posted by Michael Wonder on 09 Nov 2025
Mark Cuban Cost Plus Drug Company expands access with addition of Starjemza (ustekinumab-hmny) to give patients more power over prescription costs
6 November 2025 - New biosimilar added to portfolio reinforces the company's commitment to transparency and access
Mark Cuban Cost Plus Drug Company today announced the addition of Starjemza, a new biosimilar medication, to its growing portfolio of affordable prescription drugs.
Starjemza represents another milestone in the company's mission to expand access to specialty medicines through its transparent pricing model, giving patients and providers additional options within an increasingly complex healthcare environment.
